Navigation

Chronic iron overload (in people with thalassaemia) - desferrioxamine, deferiprone and deferasirox [ID350]

Desferrioxamine, deferiprone and deferasirox for the treatment of chronic iron overload in people with thalassaemia

Status: Suspended
Expected date of issue: TBC
Referral date: July 2010
Process: MTA
Notes:

Scoped within Batch 12

Topic area:
  • Blood and immune system
  • Endocrine, nutritional and metabolic
 

NICE project team

Executive Lead: Peter Littlejohns
Technical Lead: Raisa Sidhu
Communications manager: Shalu Kanal
Project manager: Jeremy Powell
Top


 

Provisional schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC
Top


 

Consultees and commentators

Consultees Commentators (no right to submit or appeal)

Manufacturers/sponsors

  • Apotex (deferiprone)
  • Swedish Orphan Biovitrum (deferiprone)
  • Hospira (desferrioxamine)
  • Novartis Pharmaceuticals (deferasirox, desferrioxamine)

Patient/carer groups

  • Action for Children
  • Action for Sick Children
  • Afiya Trust
  • Black Health Agency
  • Children’s Society
  • Chinese National Healthy Living Centre
  • Counsel and Care
  • Equalities National Council
  • Genetic Alliance UK
  • Muslim Council of Britain
  • Muslim Health Network
  • National Children’s Bureau
  • National Parent Partnership Network
  • Sickle Cell Society
  • South Asian Health Foundation
  • Specialised Healthcare Alliance
  • United Kingdom Thalassaemia Society
  • WellChild

Professional groups

  • British Association for Services to the Elderly
  • British Committee for Standards in Haematology
  • British Geriatric Society
  • British Society for Haematology
  • British Society for Human Genetics
  • NHS Sickle Cell & Thalassaemia Screening Programme
  • National Pharmacy Association
  • Royal College of General Practitioners
  • Royal College of Nursing
  • Royal College of Paediatrics & Child Health
  • Royal College of Pathologists
  • Royal College of Physicians
  • Royal Pharmaceutical Society
  • Royal Society of Medicine
  • UK Forum on Haemoglobin Disorders
  • United Kingdom Clinical Pharmacy Association
  • United Kingdom National Screening  Committee

Others

  • Department of Health
  • NHS Eastern and Coastal Kent Teaching
  • NHS Northamptonshire
  • Welsh Assembly Government

General

  • Board of Community Health Councils in Wales
  • British National Formulary
  • Care Quality Commission
  • Commissioning Support Appraisals Service
  • Department of Health, Social Services and Public Safety for Northern Ireland
  • Medicines and Healthcare products Regulatory Agency
  • National Association of Primary Care
  • Public Health Wales NHS Trust
  • NHS Alliance
  • NHS Commercial Medicines Unit
  • NHS Confederation
  • NHS Quality Improvement Scotland
  • Scottish Medicines Consortium

Comparator manufacturer(s)

  • None

Relevant research groups

  • MRC Clinical Trials Unit
  • National Institute for Health Research
  • Policy Research Institute on Ageing and Ethnicity
  • Research Institute for the Care of Older People

Assessment Group

  • Liverpool Reviews & Implementation Group, University of Liverpool
  • National Institute for Health Research Health Technology Assessment Programme

Associated Guideline Groups

  • National Clinical Guidelines Centre

Associated Public Health Groups

  • None

Top


 

Key documents

This page was last updated: 02 July 2012

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.